<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ANLL followed a brief period of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in a man treated intensively 4 years and 3 months previously with <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> as "adjuvant" therapy for <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This is the first reported instance in which the latency between drug exposure and <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001909'>leukemia</z:hpo> strongly implicates <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> as a leukemogenic agent </plain></SENT>
</text></document>